Medicilon Appoints Dr. Liu Jian as President, Drug Discovery Division

Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr. Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. With expertise in modern synthetic chemistry, Medicilon excels in various cutting-edge areas of pharmaceutical research, including...

The post Medicilon Appoints Dr. Liu Jian as President, Drug Discovery Division first appeared on AI-TechPark.

ai chemistry discovery drug discovery edge expertise importance innovation modern pharmaceutical platform president service synthetic